乌斯特基努马布在克罗恩氏病的有效性与肠道中的病变
Satoshi Tamura1, Yusuke Asai1, Natsuki Ishida1
1First Department of Medicine, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu, Japan.
乌斯特基努马布改善了克罗恩氏病活动指数得分,特别是在小肠病变患者中. 这种治疗对该亚组的白蛋白和血红蛋白水平有显著的改善,表明了潜在的疗效.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩氏病是一种慢性炎症状况,需要有效的治疗方法.
- 乌斯特基努马布向介质蛋白-12和23,为中度至重度病例提供治疗选择.
- 耐固醇克罗恩病是一个重大的临床挑战.
研究的目的:
- 评估乌斯特基努马布在影响小肠和/或大肠的克罗恩病患者的临床结果.
- 根据疾病活性指数和生化标志物评估乌斯提金巴的疗效.
- 检查不同患者子组的治疗保留率.
主要方法:
- 在2014年3月至2020年12月接受乌斯提金巴治疗的患者的回顾性研究.
- 主要终点:克罗恩病活动指数 (CDAI) 在基线和8,24,48周.
- 二级终点:白蛋白,血红蛋白,C-反应蛋白水平;治疗保留率.
主要成果:
- 总体而言,CDAI在48周后没有显著改善.
- 在只有小肠病变的患者中观察到显著的CDAI改善.
- 在只有小肠病变的患者中,发现了白蛋白和血红蛋白水平的显著改善.
结论:
- 乌斯特基努马布是克罗恩病的安全有效治疗方法.
- 药物可能为患有仅限小肠病变的患者提供特别的益处.
- 进一步的研究可以探索ustekinumab在特定克罗恩氏病表型中的向疗效.
更多相关视频
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
